Enhabit (EHAB) Q4 2025 Earnings
Reported Mar 4, 2026 at 7:00 PM ET · SEC Source
Q4 25 EPS
$0.14
MISS 8.44%
Est. $0.15
Q4 25 Revenue
$270.4M
MISS 0.06%
Est. $270.6M
vs S&P Since Q4 25
-8.9%
TRAILING MARKET
EHAB +1.4% vs S&P +10.3%
Full Year 2025 Results
FY 25 EPS
$0.53
MISS 5.88%
Est. $0.56
FY 25 Revenue
$1.06B
MISS 0.01%
Est. $1.06B
Market Reaction
Did EHAB Beat Earnings? Q4 2025 Results
Enhabit closed out what management described as a "pivotal year" with a Q4 2025 earnings miss on both top and bottom lines, though the underlying operational story was considerably more constructive than the headline numbers suggest. The home health … Read more Enhabit closed out what management described as a "pivotal year" with a Q4 2025 earnings miss on both top and bottom lines, though the underlying operational story was considerably more constructive than the headline numbers suggest. The home health and hospice provider reported adjusted EPS of $0.14, falling short of the $0.15 consensus estimate by 8.44%, while revenue of $270.40 million edged just 0.06% below the $270.56 million consensus, even as the top line grew 4.7% year over year. A $44.70 million goodwill impairment drove a GAAP net loss of $38.70 million for the quarter, masking genuine operational progress that included 7.3% home health admissions growth and hospice revenue climbing 10.0% to $63.60 million. The most consequential development, however, is Kinderhook Industries' agreement to acquire Enhabit for $13.80 per share in an approximately $1.10 billion deal expected to close in Q2 2026, a transaction that prompted management to suspend financial guidance entirely and forgo an earnings call, signaling the company's attention has shifted firmly toward closing the deal.
Key Takeaways
- • Home health total admissions growth of 7.3% year over year with non-Medicare admissions growth of 16.0%
- • Home health ADC growth of 6.4% year over year driven by admission volume increases
- • Hospice ADC grew 9.9% year over year with sequential increases every quarter since Q1 2024
- • Home health cost per patient day decreased 3.5% year over year on improved clinical staff productivity
- • Consolidated Adjusted EBITDA grew 11.6% year over year to $28.0 million
- • Continued stabilization of Medicare ADC decline, down 4.0% year over year vs. 11.6% decline in prior year period
- • Non-Medicare revenue per visit rose 7.5% year over year
EHAB Forward Guidance & Outlook
Given the pending merger with Kinderhook Industries, Enhabit has suspended its practice of providing financial guidance and will not host an earnings conference call. However, the company outlined 2026 operational priorities including opening 3-6 home health and 9-12 hospice de novo locations, targeting $25-$50 million in strategic M&A investment, continuing to de-lever the balance sheet, optimizing payer mix, and reducing cost per patient day in both home health and hospice segments.
EHAB YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
EHAB Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our fourth quarter 2025 results capped a pivotal year for Enhabit, delivering an emerging growth story with year over year increases in patient census, revenue and Adjusted EBITDA.”
— Barb Jacobsmeyer, Q4 2025 Earnings Press Release
EHAB Earnings Trends
EHAB vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
EHAB EPS Trend
Earnings per share: estimate vs actual
EHAB Revenue Trend
Quarterly revenue: estimate vs actual
EHAB Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 MISS FY | $0.15 | $0.14 | -8.44% | $270.4M | -0.06% |
| FY Full Year | $0.56 | $0.53 | -5.88% | $1.06B | -0.01% |
| Q3 25 BEAT | $0.12 | $0.17 | +42.38% | $263.6M | -1.33% |
| Q2 25 BEAT | $0.10 | $0.13 | +30.78% | $266.1M | +1.03% |
| Q1 25 BEAT | $0.06 | $0.10 | +60.26% | $259.9M | -2.33% |